About Admetsys
Admetsys is a company based in Boston (United States) founded in 2014. Admetsys has raised $50 thousand across 4 funding rounds from investors including T1D Exchange, Dreamit and TMCx Accelerator. Admetsys operates in a competitive market with competitors including Cellnovo, TypeZero Technologies, Pacific Diabetes Technologies, Ideal Medical Technologies and Animas, among others.
- Headquarter Boston, United States
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$50 K (USD)
in 4 rounds
-
Latest Funding Round
Not available
-
Investors
T1D Exchange
& 3 more
-
Employee Count
Not available
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Funding Insights of Admetsys
Admetsys has successfully raised a total of $50K across 4 strategic funding rounds. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Admetsys
Admetsys has secured backing from 4 investors, including institutional and venture fund investors. Prominent investors backing the company include T1D Exchange, Dreamit and TMCx Accelerator.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Startup accelerator
|
Locked | Locked | Locked | |
|
Early-stage entrepreneurs are accelerated through MassChallenge's program.
|
Locked | Locked | Locked | |
|
A nonprofit focused on type 1 diabetes research and care improvement.
|
Locked | Locked | Locked |
Investor details for Admetsys
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Admetsys
Investment portfolio details for Admetsys
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Admetsys
Detailed financials for Admetsys
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Admetsys Comparisons
Peer comparison for Admetsys
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Admetsys
Admetsys operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Cellnovo, TypeZero Technologies, Pacific Diabetes Technologies, Ideal Medical Technologies and Animas, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Offers online slot gaming with bonuses, promotions, and secure interface.
|
|
| Locked | Locked | Locked |
Device for continuous glucose monitoring with manually operated insulin delivery
|
|
| Locked | Locked | Locked |
Electronic diabetes management device for glucose sensing and hormone delivery
|
|
| Locked | Locked | Locked |
An AI-based artificial pancreas system is developed for ICU patients.
|
|
| Locked | Locked | Locked |
Device for continuous glucose monitoring with manual insulin administration
|
Detailed competitors of Admetsys
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Admetsys
Complete news archive for Admetsys
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Admetsys
Admetsys was founded in 2014.
Admetsys is headquartered in Boston, United States. It is registered at Boston, Massachusetts, United States.
Admetsys is a funded company, having raised a total of $50K across 4 funding rounds to date.
Provider of a closed-loop system for insulin and glucose delivery. The companys products provide hospitals with full automation of glucose monitoring and treatment and offer the precision and repeatability required by hospitals worldwide for this critical aspect of patient care. The Admetsys Smart Pancreas attaches to a patients existing intravenous line, where it automatically measures the blood glucose concentration in real-time and with no blood loss.
Admetsys's top competitors include TypeZero Technologies, Ideal Medical Technologies and Pacific Diabetes Technologies.
Admetsys has 4 investors. Key investors include T1D Exchange, Dreamit, TMCx Accelerator, and MassChallenge.